SAN JOSE, Calif., June 11, 2026
Anixa Biosciences, Inc. announced that two of its clinical-stage cancer immunotherapy programs will be featured at the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy Symposium, scheduled for June 22–23, 2026, at Memorial Sloan Kettering Cancer Center in New York City. The presentations will showcase progress from the company’s Phase 1 ovarian cancer CAR-T therapy program, lira-cel, and its Phase 1 breast cancer vaccine program, highlighting encouraging clinical findings and the strength of Anixa’s collaborations with leading cancer research institutions.
Lira-cel CAR-T Program Shows Encouraging Progress in Ovarian Cancer
Anixa Biosciences will present updates from its ongoing Phase 1 clinical trial of liraltagene autoleucel (lira-cel), an investigational CAR-T therapy designed to treat patients with recurrent ovarian cancer. The therapy uniquely targets the follicle-stimulating hormone receptor (FSHR), a protein selectively expressed on ovarian cancer cells and tumor-associated vasculature while showing limited expression in healthy tissues. The presentation will include trial design details, study objectives, and positive survival observations reported from patients enrolled in the ongoing study. Lira-cel is being developed in collaboration with Moffitt Cancer Center, with contributions from researchers at Roswell Park Comprehensive Cancer Center, University of Chicago School of Medicine, and Duke University Medical Center. The program represents a novel approach to cell therapy for solid tumors, an area where CAR-T therapies have historically faced significant development challenges.
Breast Cancer Vaccine Achieves Key Phase 1 Endpoints
The company will also present final data from its Phase 1 breast cancer vaccine trial, which successfully achieved all major primary study endpoints. According to the results, the investigational vaccine demonstrated a favorable safety and tolerability profile at the maximum tolerated dose while generating protocol-defined immune responses in 74% of study participants. The vaccine is designed around alpha-lactalbumin (α-lactalbumin), a protein associated with lactation that is abnormally expressed in certain breast cancers. By training the immune system to recognize this target, the vaccine aims to prevent or treat breast cancer while minimizing effects on normal tissues. Researchers will also present immunohistochemistry findings confirming alpha-lactalbumin expression in tumor samples, providing additional biological support for the vaccine’s mechanism of action.
Advertisement
Strategic Collaborations Advance Cancer Immunotherapy Pipeline
The presentations highlight Anixa’s collaborative development model, which combines biotechnology innovation with expertise from leading academic and clinical institutions. The ovarian cancer CAR-T program is being advanced through partnerships with major cancer centers specializing in immunotherapy, while the breast cancer vaccine program is being developed in collaboration with the Cleveland Clinic Cancer Institute. Company leadership believes these partnerships accelerate clinical development and strengthen the scientific foundation of its immunotherapy programs. The symposium provides an opportunity to share emerging clinical findings with oncology researchers, clinicians, and industry leaders focused on next-generation cancer treatments.
Expanding Immunotherapy Opportunities Across Multiple Cancer Types
Beyond ovarian and breast cancer, Anixa continues to advance a broader pipeline of immunotherapy programs targeting difficult-to-treat malignancies. The company’s vaccine platform focuses on “retired” proteins that are no longer needed in healthy adult tissues but are expressed in various cancers, potentially creating highly selective therapeutic targets. With ongoing clinical development and growing interest in cell therapies and cancer vaccines, Anixa aims to expand its approach into additional tumor types, including ovarian, lung, colon, and prostate cancers. The upcoming symposium presentations represent another milestone in demonstrating the clinical potential of the company’s innovative immunotherapy portfolio.
Source: Anixa Biosciences press release
